165 related articles for article (PubMed ID: 29938344)
1. Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
Kalra S; Kaur RP; Ludhiadch A; Shafi G; Vashista R; Kumar R; Munshi A
Eur J Clin Pharmacol; 2018 Oct; 74(10):1291-1298. PubMed ID: 29938344
[TBL] [Abstract][Full Text] [Related]
2. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.
Jamieson D; Lee J; Cresti N; Jackson R; Griffin M; Sludden J; Verrill M; Boddy AV
Cancer Chemother Pharmacol; 2014 Oct; 74(4):667-74. PubMed ID: 25055937
[TBL] [Abstract][Full Text] [Related]
5. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
[TBL] [Abstract][Full Text] [Related]
6. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
7. Combined expression of aldehyde dehydrogenase 1A1 and β-catenin is associated with lymph node metastasis and poor survival in breast cancer patients following cyclophosphamide treatment.
Sun M; Zhao H; Xiao Q; Yu Z; Song Z; Yao W; Tang H; Guan S; Jin F; Wei M
Oncol Rep; 2015 Dec; 34(6):3163-73. PubMed ID: 26398662
[TBL] [Abstract][Full Text] [Related]
8. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
9. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
[TBL] [Abstract][Full Text] [Related]
11. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
12. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
[No Abstract] [Full Text] [Related]
13. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas KS; Yao TJ; Norton L
J Clin Oncol; 1999 Apr; 17(4):1118. PubMed ID: 10561169
[TBL] [Abstract][Full Text] [Related]
14. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
Sreerama L; Sládek NE
Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
[TBL] [Abstract][Full Text] [Related]
15. Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
Bontenbal M; van Putten WL; Burghouts JT; Baggen MG; Ras GJ; Stiegelis WF; Beudeker M; Janssen JT; Braun JJ; van der Linden GH; van der Velden PC; van Geel AN; Helle P; Leisink M; Foekens JA; Klijn JG
J Clin Oncol; 2000 Feb; 18(4):734-42. PubMed ID: 10673514
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Damkier P; Kjærsgaard A; Barker KA; Cronin-Fenton D; Crawford A; Hellberg Y; Janssen EAM; Langefeld C; Ahern TP; Lash TL
Sci Rep; 2017 Aug; 7(1):7727. PubMed ID: 28798474
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.
Veal GJ; Cole M; Chinnaswamy G; Sludden J; Jamieson D; Errington J; Malik G; Hill CR; Chamberlain T; Boddy AV
Eur J Cancer; 2016 Mar; 55():56-64. PubMed ID: 26773420
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients.
Yaghan RJ; Dagher NM
Asian Pac J Cancer Prev; 2016; 17(8):4031-5. PubMed ID: 27644657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
